- Proffered paper oral presentation at ESMO 2023 scheduled
for Monday, October 23, 2023, at
8:50 am CEST will be presented by Dr.
Meredith McKean, Sara Cannon
Research Institute
- Darovasertib and Crizotinib combination observed manageable
safety profile and clinical efficacy that appears superior to
current standard of care in MUM
- Clinical data update, will include confirmed ORR by RECIST
1.1 by HLA-A2 status, median progression free survival,
HLA-A2(+) and (-) status prevalence across darovasertib clinical
trials, and ctDNA molecular response rate
- Press release summarizing the top-line results will be
available on Monday, October 23,
2023, at approximately 6:00 am
ET
SOUTH
SAN FRANCISCO, Calif., Oct. 17,
2023 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(Nasdaq:IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, announces
the publication of the abstract for a proffered paper session at
the European Society of Medical Oncology Congress 2023 (ESMO 2023)
relating to selected clinical data from the company's ongoing Phase
2 clinical trial evaluating darovasertib in combination with
crizotinib in patients having metastatic uveal melanoma (MUM).
Dr. Meredith McKean, M.D., MPH,
Director, Melanoma and Skin Cancer Research at Sarah Cannon
Research Institute, who is a clinical investigator on the Phase 2
clinical trial, will present the clinical data as summarized in the
abstract, as follows:
- Session No. 1081O
- Title: ctDNA reduction and clinical efficacy of the
darovasertib + crizotinib (Daro + Crizo) combination in metastatic
uveal melanoma (MUM)
- Date: Monday, October 23, 2023 at
8:50-9:00 am CEST
- Dr. Meredith McKean, M.D., MPH,
Sarah Cannon Research Institute (Nashville, TN, U.S.A)
In summary, the Phase 2 evaluation of the darovasertib and
crizotinib combination in first-line and pretreated MUM patients
showed a manageable safety profile and demonstrated clinical
efficacy that appears superior to current standards of care.
Human leukocyte antigen (HLA)-A*02:01 (HLA-A2) status was
determined in a subset of patients enrolled in the company's
clinical trials evaluating darovasertib. Clinical efficacy was
observed in both HLA-A2 positive (HLA-A2(+)) and HLA-A2 negative
(HLA-A2(-)) patients. ctDNA was reduced in almost all patients and
ctDNA molecular responses were deep and sustained in the majority
of patients.
The reported data support IDEAYA's ongoing registrational Phase
2/3 study for potential accelerated approval of darovasertib and
crizotinib for treatment of first-line HLA-A2(-) MUM patients,
where there are no FDA approved therapies.
A press release summarizing the top-line results will be
available on Monday, October 23,
2023, at approximately 6:00 am
ET, and will be available on the Company's website, at its
Investor Relations portal (https://ir.ideayabio.com/).
About IDEAYA Biosciences
IDEAYA is a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its
research and drug discovery capabilities to synthetic lethality –
which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to the timing and content of the ESMO 2023
presentation and related press release. IDEAYA undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of IDEAYA in general, see IDEAYA's Quarterly Report on
Form 10-Q filed on August 10, 2023
and any current and periodic reports filed with the U.S. Securities
and Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2023-for-phase-2-clinical-data-update-for-darovasertib-and-crizotinib-combination-in-metastatic-uveal-melanoma-301958315.html
SOURCE IDEAYA Biosciences, Inc.